Mcdonald Capital Investors Inc. CA Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mcdonald Capital Investors Inc. CA increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 170,180 shares of the biopharmaceutical company’s stock after acquiring an additional 33,727 shares during the quarter. Regeneron Pharmaceuticals makes up about 7.6% of Mcdonald Capital Investors Inc. CA’s portfolio, making the stock its 6th largest position. Mcdonald Capital Investors Inc. CA owned approximately 0.15% of Regeneron Pharmaceuticals worth $121,224,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of REGN. CWA Asset Management Group LLC bought a new position in Regeneron Pharmaceuticals during the third quarter worth $298,000. Sigma Planning Corp lifted its stake in shares of Regeneron Pharmaceuticals by 4.1% in the third quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company’s stock valued at $430,000 after buying an additional 16 shares in the last quarter. Baker Avenue Asset Management LP bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at $707,000. Ashton Thomas Securities LLC lifted its stake in shares of Regeneron Pharmaceuticals by 10.5% in the third quarter. Ashton Thomas Securities LLC now owns 790 shares of the biopharmaceutical company’s stock valued at $830,000 after buying an additional 75 shares in the last quarter. Finally, Peregrine Asset Advisers Inc. bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at $424,000. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on REGN. Citigroup dropped their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Robert W. Baird lowered their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Bank of America reiterated an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Finally, BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $707.51 on Monday. The firm has a 50 day moving average of $696.12 and a 200-day moving average of $848.69. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The firm has a market capitalization of $77.35 billion, a P/E ratio of 18.48, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the business earned $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.50%. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.